NCT00599612View on ClinicalTrials.gov

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 17, 2008

Primary Completion Date

February 18, 2008

Study Completion Date

February 18, 2008

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GW856553

A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.

Trial Locations (1)

EH33 2NE

GSK Investigational Site, Edinburgh

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY